BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Nov 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
5/8 — Partial
Priority Review
RITUXAN (rituximab) by Roche is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 1997.
Drug data last refreshed 13h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RITUXAN (rituximab) is a CD20-directed monoclonal antibody approved in 1997 that works by targeting and eliminating B cells expressing the CD20 antigen. It is used across multiple indications including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and certain autoimmune conditions. The drug functions as a cytolytic antibody that induces B cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
$0.039BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Part D spending; commercial teams focus on defending market share against biosimilars and newer mechanisms.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
Started Oct 2026
30 enrolled
Classic Follicular LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+1 more
Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
Started Oct 2026
18 enrolled
Large B-cell LymphomaCentral Nervous System Lymphoma
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Started Sep 2026
15 enrolled
Non Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma+7 more
Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)
Started Aug 2026
23 enrolled
Post-transplant Lymphoproliferative Disorder
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Started Jun 2026
960 enrolled
Follicular Lymphoma
Worked on RITUXAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.